3.57
+0.04(+1.13%)
Currency In USD
| Previous Close | 3.53 |
| Open | 3.67 |
| Day High | 3.89 |
| Day Low | 3.27 |
| 52-Week High | 9.5 |
| 52-Week Low | 1.61 |
| Volume | 4.39M |
| Average Volume | 1.23M |
| Market Cap | 228.58M |
| PE | -2.36 |
| EPS | -1.51 |
| Moving Average 50 Days | 2.86 |
| Moving Average 200 Days | 3.92 |
| Change | 0.04 |
If you invested $1000 in Larimar Therapeutics, Inc. (LRMR) 10 years ago, it would be worth $8.32 as of July 30, 2025 at a share price of $3.57. Whereas If you bought $1000 worth of Larimar Therapeutics, Inc. (LRMR) shares 5 years ago, it would be worth $310.43 as of July 30, 2025 at a share price of $3.57.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Larimar Therapeutics Announces Pricing of Underwritten Public Offering
GlobeNewswire Inc.
19 hours ago
BALA CYNWYD, Pa., July 29, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the pricing of its previou
Larimar Therapeutics Announces Proposed Underwritten Public Offering
GlobeNewswire Inc.
Yesterday at 8:01 PM GMT
BALA CYNWYD, Pa., July 29, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that it has commenced an u
Larimar Therapeutics Publishes Nonclinical Data Supporting the Therapeutic Potential of Nomlabofusp in Patients with Friedreich’s Ataxia
GlobeNewswire Inc.
Jul 08, 2025 11:00 AM GMT
Nonclinical findings provide evidence of the mechanism of action of nomlabofusp and support the potential use of skin FXN concentrations as a novel surrogate endpoint for Larimar’s planned BLA submission in Q2 2026 seeking accelerated approval BALA C